Skip to main content
SpringerLink
Log in

Colloidal Gold: A Novel Nanoparticle for Targeted Cancer Therapeutics

  • Protocol
  • First Online:
Cancer Nanotechnology

Part of the book series: Methods in Molecular Biology ((MIMB,volume 624))

Abstract

Since their initial description in 1857, gold nanoparticles have been used extensively in the fields of diagnostics and therapeutics. Now, gold nanoparticles are engineered to target the delivery of potent anti-cancer therapeutics to solid tumors to improve either their safety or efficacy or both. Described in this chapter is the development of one such nanotherapeutic, termed CYT-6091, that targets the delivery of tumor necrosis factor alpha (TNF) to solid tumors. Outlined in the presentation is a discussion of nanoparticles and specifically colloidal gold, an historical review on the biology of TNF and its limited use in the clinic when administered systemically, and finally, how gold nanoparticles bound with TNF may improve the safety and efficacy profiles of TNF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferrari, M. (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3), 161–171.

    Article  CAS  PubMed  Google Scholar 

  2. Sinha, R., Kim, G. J., Nie, S., and Shin, D. M. (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5(8), 1909–1917.

    Article  CAS  PubMed  Google Scholar 

  3. Nie, S., Xing, Y., Kim, G. J., and Simons, J. W. (2007) Nanotechnology applications in cancer. Annu Rev Biomed Eng 9, 257–288.

    Article  CAS  PubMed  Google Scholar 

  4. Carmeliet, P. and Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407(6801), 249–257.

    Article  CAS  PubMed  Google Scholar 

  5. Nagayasu, A., Uchuyama, K., and Kiwada, H. (1999) The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 40(1–2), 75–87.

    Article  CAS  PubMed  Google Scholar 

  6. Klibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P., and Huang, L. (1991) Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1062(2), 142–148.

    Article  CAS  PubMed  Google Scholar 

  7. Park, J. W. (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4(3), 95–99.

    Article  CAS  PubMed  Google Scholar 

  8. Paciotti, G. F., Myer, L., Weinrich, D., et al. (2004) Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 11(3), 169–183.

    Article  CAS  PubMed  Google Scholar 

  9. Farma, J., Puhlmann, M., Soriano, P. A., et al. (2007) Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer 120(11), 2474–2480.

    Article  CAS  PubMed  Google Scholar 

  10. Faraday, M. (1857) Experimental relations of gold (and other metals) to light. Philos Trans R Soc Lond B Biol Sci 14, 145–181.

    Google Scholar 

  11. Gottlieb, N. L. and Gray, R. G. (1981) Pharmacokinetics of gold in rheumatoid arthritis. Agents Actions Suppl 8, 529–538.

    CAS  PubMed  Google Scholar 

  12. Rubin, P. and Levitt, S. H. (1964) The response of disseminated reticulum cell sarcoma to the intravenous injection of colloidal radioactive gold. J Nucl Med 5, 581–594.

    CAS  PubMed  Google Scholar 

  13. Root, S. W., Andrews, G. A., Kniseley, R. M., and Tyor, M. P. (1954) The distribution and radiation effects of intravenously administered colloidal Au198 in man. Cancer 7(5), 856–866.

    Article  CAS  PubMed  Google Scholar 

  14. Holbrook, M. A., Welch, J. S., and Childs, D. S. (1964) Adjuvant use of radioactive colloids in the treatment of carcinoma of the ovary. Radiology 83, 888–891.

    CAS  PubMed  Google Scholar 

  15. Fountain, K. S. and Malkasian, G. D. (1981) Radioactive colloidal gold in the treatment of endometrial cancer. Cancer 47, 2430–2432.

    Article  CAS  PubMed  Google Scholar 

  16. Renaud, G., Hamilton, R. L., and Havel, R. J. (1989) Hepatic metabolism of colloidal gold-low-density-lipoprotein complexes in the rat: evidence for bulk excretion of lysosomal contents into bile. Hepatology 9(3), 380–392.

    Article  CAS  PubMed  Google Scholar 

  17. Hardonk, M. J., Harms, G., and Koudstaal, J. (1985) Zonal heterogeneity of rat hepatocytes in the in vivo uptake of 17 nm colloidal gold granules. Histochem 83, 473–477.

    Article  CAS  Google Scholar 

  18. Carswell, E. A., Old, L. J., Kassel, R. L., et al. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72(9), 3666–3670.

    Article  CAS  PubMed  Google Scholar 

  19. Selby, P., Hobbs, S., Jackson, E., et al. (1987) Tumour necrosis factor in man: Clinical and biological observations. Br J Cancer 56(6), 803–808.

    CAS  PubMed  Google Scholar 

  20. Pennica, D., Nedwin, G. E., Hayflick, J. S., et al. (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312(5996), 724–729.

    Article  CAS  PubMed  Google Scholar 

  21. Chen, G. and Goeddel, D. V. (2002) TNF-RI signaling: a beautiful pathway. Science 296(5573), 1634–5.

    Article  Google Scholar 

  22. Frei, E., 3rd and Spriggs, D. (1989) Tumour necrosis factor: still a promising agent. J Clin Oncol 7(3), 291–294.

    PubMed  Google Scholar 

  23. Chapman, P. B., Lester, T. J., Casper, E. S., et al. (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5(12), 1942–1951.

    CAS  PubMed  Google Scholar 

  24. Jakubowski, A. A., Casper, E. S., Gabrilove, J. L., et al. (1989) Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer. J Clin Oncol 7(3), 298–303.

    CAS  PubMed  Google Scholar 

  25. Gamm, H., Lindemann, A., Mertelsmann, R., and Herrmann, F. (1991) Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy. Eur J Cancer 27(7), 856–863.

    Article  CAS  PubMed  Google Scholar 

  26. Creaven, P. J., Plager, J. E., Dupere, S., et al. (1987) Phase I Clinical Trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20(2), 137–144.

    CAS  PubMed  Google Scholar 

  27. Taguchi, T. (1988) Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050). Cancer Detect Prev 12(1–6), 561–572.

    CAS  PubMed  Google Scholar 

  28. Kemeny, N., Childs, B., Larchian, W., et al. (1990) A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 66(4), 659–663.

    Article  CAS  PubMed  Google Scholar 

  29. Lenk, H., Tanneberger, S., Muller, U., et al. (1989) Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 24(6), 391–2.

    Article  Google Scholar 

  30. Feldman, E. R., Creagan, E. T., Schaid, D. J., and Ahmann, D. L. (1992) Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma. Am J Clin Oncol 15(3), 256–259.

    Article  CAS  PubMed  Google Scholar 

  31. Budd, G. T., Green, S., Baker, L. H., et al. (1991) A southwest oncology group phase ii trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer 68(8), 1694–5.

    Article  Google Scholar 

  32. Haranaka, K., Satomi, N., and Sakurai, A. (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34(2), 263–267.

    Article  CAS  PubMed  Google Scholar 

  33. Lienard, D., Ewalenko, P., Delmotte, J. J., et al. (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10(1), 52–60.

    CAS  PubMed  Google Scholar 

  34. Fraker, D. L., Alexander, H. R., Andrich, M., and Rosenberg, S. A. (1996) Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 14(2), 479–489.

    CAS  PubMed  Google Scholar 

  35. Dvorak, A. M., Kohn, S., Morgan, E. S., et al. (1996) The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol 59(1), 100–115.

    CAS  PubMed  Google Scholar 

  36. Feng, D., Nagy, J., Hipp, J., et al. (1996) Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med 183(5), 1981–1986.

    Article  CAS  PubMed  Google Scholar 

  37. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., and McDonald, D. M. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4), 1363–1380.

    CAS  PubMed  Google Scholar 

  38. Jain, R. K. (2003) Molecular regulation of vessel maturation. Nat Med 9(6), 685–693.

    Article  CAS  PubMed  Google Scholar 

  39. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. New Engl J Med 285(21), 1182–1186.

    Article  CAS  PubMed  Google Scholar 

  40. Hermanson, G. T. (1996) Preparation of colloidal-gold labeled proteins. in Bioconjugate Techniques. Academic Press, Inc., San Diego, pp. 594–597.

    Google Scholar 

  41. Libutti, S. K., Paciotti, G. F., Myer, L., et al. Preliminary results of a phase I clinical trial of CYT-6091: A pegylated colloidal-gold TNF. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings, Part I. Vol 25, No. 18S (June 20 Supplement), 3603.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, Bethesda, MD, USA

    Anathea C. Powell & Steven K. Libutti

  2. CytImmune Sciences, Inc., Rockville, MD, USA

    Giulio F. Paciotti

Authors
  1. Anathea C. Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulio F. Paciotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven K. Libutti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Surgery, University of Florida, Gainesville, USA

    Stephen R. Grobmyer

  2. ERC - Engineering Research Center, University of Florida, Gainesville, USA

    Brij M. Moudgil

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Powell, A.C., Paciotti, G.F., Libutti, S.K. (2010). Colloidal Gold: A Novel Nanoparticle for Targeted Cancer Therapeutics. In: Grobmyer, S., Moudgil, B. (eds) Cancer Nanotechnology. Methods in Molecular Biology, vol 624. Humana Press. https://doi.org/10.1007/978-1-60761-609-2_25

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-609-2_25

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-608-5

  • Online ISBN: 978-1-60761-609-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation